logo-loader
ASX:SNT

Syntara Ltd

Receive alerts
Market:
ASX
Price
0.02 AUD
Day Change
-
Market Cap:
$23.88 m
52 weeks high
0.06
52 weeks low
0.02

In brief

Syntara Ltd is a clinical-stage drug development company focused on the development of novel therapeutics aimed at correcting extracellular matrix (ECM) dysfunction.

This will lead to positive outcomes in a range of diseases with high unmet need, including haematological malignancies such as myelofibrosis and myelodysplastic syndrome, chronic fibrosis (including skin scarring, pulmonary fibrosis, chronic kidney disease, NASH and cardiac fibrosis) and neuroinflammation.

Snapshot

  • Syntara adds new blood cancer indication to SNT-5505 development plan following government grant
  • Pharmaxis’ treatment to prevent wound and burns scars clears phase1 trial
  • Syntara to start Phase 2 study targeting MDS